BR9811042A - Composto, formulação farmacêutica, uso de um composto, e, processos para o tratamento de distúrbios no sistema nervoso central e/ou de incontinência urinária, vasoespasmos e controle do crescimento de tumores e para a preparação do composto - Google Patents

Composto, formulação farmacêutica, uso de um composto, e, processos para o tratamento de distúrbios no sistema nervoso central e/ou de incontinência urinária, vasoespasmos e controle do crescimento de tumores e para a preparação do composto

Info

Publication number
BR9811042A
BR9811042A BR9811042-0A BR9811042A BR9811042A BR 9811042 A BR9811042 A BR 9811042A BR 9811042 A BR9811042 A BR 9811042A BR 9811042 A BR9811042 A BR 9811042A
Authority
BR
Brazil
Prior art keywords
compound
alkyl
preparation
disorders
processes
Prior art date
Application number
BR9811042-0A
Other languages
English (en)
Inventor
Stefan Berg
Mats Linderberg
Svante Ross
Seth Olov Thorberg
Bengt Ulff
Original Assignee
Astra Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astra Ab filed Critical Astra Ab
Publication of BR9811042A publication Critical patent/BR9811042A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
    • C07D295/18—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carboxylic acids, or sulfur or nitrogen analogues thereof
    • C07D295/182—Radicals derived from carboxylic acids
    • C07D295/192—Radicals derived from carboxylic acids from aromatic carboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/24—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a ring other than a six-membered aromatic ring of the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/12—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms
    • C07D295/135—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/14—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D295/155—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with the ring nitrogen atoms and the carbon atoms with three bonds to hetero atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
    • C07D295/20—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carbonic acid, or sulfur or nitrogen analogues thereof
    • C07D295/205—Radicals derived from carbonic acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00—Systems containing two condensed rings
    • C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
    • C07C2602/04—One of the condensed rings being a six-membered aromatic ring
    • C07C2602/10—One of the condensed rings being a six-membered aromatic ring the other ring being six-membered, e.g. tetraline

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Obesity (AREA)
  • Gynecology & Obstetrics (AREA)
  • Hospice & Palliative Care (AREA)
  • Child & Adolescent Psychology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Vascular Medicine (AREA)
  • Addiction (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

"COMPOSTO, FORMULAçãO FARMACêUTICA, USO DE UM COMPOSTO, E, PROCESSOS PARA O TRATAMENTO DE DISTúRBIOS NO SISTEMA NERVOSO CENTRAL E/OU DE INCONTINêNCIA URINáRIA, VASOESPASMOS E CONTROLE DO CRESCIMENTO DE TUMORES E PARA A PREPARAçãO DO COMPOSTO" A presente invenção diz respeito a novos derivados de 1,2,3,4-tetraidronaftaleno substituídos por piperidila ou piperazinila que tem a fórmula (I) em que X é N ou CH; Y é NR~ 2~CH~ 2~, CH~ 2~-NR~ 2~, NR~ 2~-CO, CO-NR~ 2~ ou NR~ 2~SO~ 2~ em que R~ 2~ é H ou alquila C~ 1~-C~ 6~; R~ 1~ é H, alquila C~ 1~-C~ 6~ ou cicloalquila C~ 3~-C~ 6~; R~ 3~ é alquila C~ 1~-C~ 6~, cicloalquila C~ 3~-C~ 6~ ou (CH~ 2~)~ n~-arila, em que a arila é fenila ou um anel heteroaromático contendo um ou dois heteroátomos selecionados de N, O e S e que pode ser mono ou di-substituído, n é de 0 a 4; R~ 9~ é alquila C~ 1~-C~ 6~, cicloalquila C~ 3~-C~ 6~, OCF~ 3~, OCHF~ 2~, OCH~ 2~F, halogênio, CN, CF~ 3~, OH, alcoxi C~ 1~-C~ 6~, alcoxi C~ 1~-C~ 6~ alquila C~ 1~-C~ 6~, NR~ 6~R~ 7~, SO~ 3~CH~ 3~, SO~ 3~CF~ 3~, SO~ 2~NR~ 6~R~ 7~, um anel heterocíclico ou heteroaromático, não substituído ou substituído, contendo um ou dois heteroátomos selecionados de N e O, em que o(s) substituinte(s) é(são) alquila C~ 1~-C~ 6~; ou COR~ 8~; em que R~ 6~, R~ 7~ e R~ 8~ são como definidos acima, como (R)-enantiómeros, (S)-enantiómeros ou racematos na forma de uma base livre ou sais destes farmaceuticamente aceitáveis, a um processo para sua preparação, a composições farmacêuticas que contém os ditos compostos terapeuticamente ativos e ao uso dos ditos compostos ativos em terapia.
BR9811042-0A 1997-07-25 1998-07-15 Composto, formulação farmacêutica, uso de um composto, e, processos para o tratamento de distúrbios no sistema nervoso central e/ou de incontinência urinária, vasoespasmos e controle do crescimento de tumores e para a preparação do composto BR9811042A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE9702799A SE9702799D0 (sv) 1997-07-25 1997-07-25 New compounds
PCT/SE1998/001390 WO1999005134A1 (en) 1997-07-25 1998-07-15 Substituted 1,2,3,4-tetrahydronaphthalene derivatives

Publications (1)

Publication Number Publication Date
BR9811042A true BR9811042A (pt) 2000-08-15

Family

ID=20407828

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9811042-0A BR9811042A (pt) 1997-07-25 1998-07-15 Composto, formulação farmacêutica, uso de um composto, e, processos para o tratamento de distúrbios no sistema nervoso central e/ou de incontinência urinária, vasoespasmos e controle do crescimento de tumores e para a preparação do composto

Country Status (37)

Country Link
US (3) US6313118B1 (pt)
EP (1) EP1000048B1 (pt)
JP (1) JP3895923B2 (pt)
KR (1) KR20010022171A (pt)
CN (1) CN1270585A (pt)
AR (2) AR013370A1 (pt)
AT (1) ATE228510T1 (pt)
AU (1) AU739569B2 (pt)
BR (1) BR9811042A (pt)
CA (1) CA2296518A1 (pt)
DE (1) DE69809755T2 (pt)
DK (1) DK1000048T3 (pt)
DZ (1) DZ2569A1 (pt)
EE (1) EE04238B1 (pt)
ES (1) ES2187983T3 (pt)
HK (1) HK1025963A1 (pt)
HR (1) HRP980404B1 (pt)
HU (1) HUP0004334A3 (pt)
ID (1) ID24583A (pt)
IL (1) IL134108A0 (pt)
IS (1) IS5358A (pt)
MA (1) MA26521A1 (pt)
NO (1) NO315609B1 (pt)
NZ (1) NZ502384A (pt)
PL (1) PL338563A1 (pt)
PT (1) PT1000048E (pt)
RU (1) RU2194696C2 (pt)
SE (1) SE9702799D0 (pt)
SI (1) SI1000048T1 (pt)
SK (1) SK283918B6 (pt)
TN (1) TNSN98141A1 (pt)
TR (1) TR200000229T2 (pt)
TW (1) TW438781B (pt)
UA (1) UA69389C2 (pt)
WO (1) WO1999005134A1 (pt)
YU (1) YU2300A (pt)
ZA (1) ZA986588B (pt)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9601110D0 (sv) * 1996-03-22 1996-03-22 Astra Ab Substituted 1,2,3,4-tetrahydronaphthalene derivatives
SE9900190D0 (sv) * 1999-01-22 1999-01-22 Astra Ab New compounds
SE9904724D0 (sv) * 1999-12-22 1999-12-22 Carlsson A Research Ab New modulators of dopamine neurotransmission I
SE0002729D0 (sv) * 2000-07-20 2000-07-20 Astrazeneca Ab Novel compound form
AR034206A1 (es) * 2001-02-16 2004-02-04 Solvay Pharm Bv Un procedimiento para la preparacion de mesilatos de derivados de piperazina y dichos mesilatos
SE0102856D0 (sv) * 2001-08-27 2001-08-27 Astrazeneca Ab A new method
SE0103644D0 (sv) * 2001-11-01 2001-11-01 Astrazeneca Ab Therapeutic isoquinoline compounds
US7101881B2 (en) * 2003-06-11 2006-09-05 Pfizer Inc Tetrahydroquinolines
SE0301798D0 (sv) * 2003-06-19 2003-06-19 Astrazeneca Ab New use IV
SE0301794D0 (sv) * 2003-06-19 2003-06-19 Astrazeneca Ab New use III
WO2005113527A1 (en) * 2004-05-21 2005-12-01 Pfizer Products Inc. Tetrahydronaphthyl- piperazines as 5-ht1b antagonists, inverse agonists and partial agonists
US20080033050A1 (en) * 2006-08-04 2008-02-07 Richards Patricia Allison Tewe Method of treating thermoregulatory disfunction with paroxetine
WO2008130323A1 (en) * 2007-04-23 2008-10-30 Astrazeneca Ab Novel 8-piperazine-tetrahydronaphtalene derivatives for the treatment of pain
WO2008130319A2 (en) * 2007-04-23 2008-10-30 Astrazeneca Ab Novel n-tetrahydronaphtalene or n-chromane carboxamide derivatives for the treatment of pain
WO2008130322A1 (en) * 2007-04-23 2008-10-30 Astrazeneca Ab Novel 5-heterocyclyl-chromane derivatives for the treatment of pain
WO2008130321A2 (en) * 2007-04-23 2008-10-30 Astrazeneca Ab Novel n-tetrahydronaphtalene or 5-heterocyclyl-chromane or 8-heterocyclyl-tetrahydronaphtalene derivatives for the treatment of pain
SA08290245B1 (ar) * 2007-04-23 2012-02-12 استرازينيكا ايه بي مشتقات كربو كساميد جديدة من -n (8-اريل رباعي هيدرو نفثالين غير متجانس- 2- يل) أو -n (5-اريل كرومان غير متجانس -3-يل) لعلاج الألم
EP2098511A1 (en) 2008-03-07 2009-09-09 Solvias AG Process for preparing compounds containing a hydronaphtalene structure with an unsymmetrically substituted benzene ring
ME01516B (me) 2008-06-20 2014-04-20 Astrazeneca Ab DERIVAT DIBENZOTIAZEPINA l NJEGOVA UPOTREBA
GB201002563D0 (en) 2010-02-15 2010-03-31 Cambridge Entpr Ltd Compounds
GB201111705D0 (en) 2011-07-07 2011-08-24 Takeda Pharmaceutical Compounds and their use
GB201111704D0 (en) 2011-07-07 2011-08-24 Takeda Pharmaceutical Novel compounds
JO3115B1 (ar) 2011-08-22 2017-09-20 Takeda Pharmaceuticals Co مركبات بيريدازينون واستخدامها كمثبطات daao
GB201209587D0 (en) 2012-05-30 2012-07-11 Takeda Pharmaceutical Therapeutic compounds
CA2914263C (en) 2013-06-21 2021-05-18 Takeda Pharmaceutical Company Limited 1-sulfonyl piperidine derivatives as modulators of prokineticin receptors
GB201314286D0 (en) 2013-08-08 2013-09-25 Takeda Pharmaceutical Therapeutic Compounds
GB201318222D0 (en) 2013-10-15 2013-11-27 Takeda Pharmaceutical Novel compounds
GB201320905D0 (en) 2013-11-27 2014-01-08 Takeda Pharmaceutical Therapeutic compounds
TW201613864A (en) 2014-02-20 2016-04-16 Takeda Pharmaceutical Novel compounds
GB201616839D0 (en) 2016-10-04 2016-11-16 Takeda Pharmaceutical Company Limited Therapeutic compounds
GB201619514D0 (en) 2016-11-18 2017-01-04 Takeda Pharmaceuticals Co Novel compounds
JP2021138648A (ja) 2020-03-04 2021-09-16 武田薬品工業株式会社 経口固形製剤

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3919624A1 (de) 1989-06-15 1990-12-20 Boehringer Ingelheim Kg Neue 2,5-diaminotetraline, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel
GB9119920D0 (en) 1991-09-18 1991-10-30 Glaxo Group Ltd Chemical compounds
EP0533268B1 (en) 1991-09-18 2001-08-16 Glaxo Group Limited Benzanilide derivatives as 5-HT1D antagonists
GB9119932D0 (en) 1991-09-18 1991-10-30 Glaxo Group Ltd Chemical compounds
DK148392D0 (da) 1992-12-09 1992-12-09 Lundbeck & Co As H Heterocykliske forbindelser
GB2273930A (en) 1992-12-30 1994-07-06 Glaxo Group Ltd Benzanilide derivatives
AU6391894A (en) * 1993-03-16 1994-10-11 Pfizer Inc. Naphthalene derivatives
WO1995011243A1 (en) 1993-10-19 1995-04-27 Smithkline Beecham Plc Benzanilide derivatives as 5ht-1d receptor antagonists
SE9601110D0 (sv) 1996-03-22 1996-03-22 Astra Ab Substituted 1,2,3,4-tetrahydronaphthalene derivatives

Also Published As

Publication number Publication date
SK188399A3 (en) 2000-07-11
DZ2569A1 (fr) 2003-02-15
HUP0004334A2 (en) 2001-03-28
NO20000356L (no) 2000-03-27
DE69809755T2 (de) 2003-07-17
CN1270585A (zh) 2000-10-18
IL134108A0 (en) 2001-04-30
YU2300A (sh) 2002-10-18
HRP980404B1 (en) 2002-10-31
EE200000041A (et) 2000-10-16
JP2001510837A (ja) 2001-08-07
US6534652B2 (en) 2003-03-18
PL338563A1 (en) 2000-11-06
EP1000048A1 (en) 2000-05-17
SE9702799D0 (sv) 1997-07-25
ZA986588B (en) 1999-01-25
SI1000048T1 (en) 2003-04-30
EP1000048B1 (en) 2002-11-27
WO1999005134A1 (en) 1999-02-04
MA26521A1 (fr) 2004-12-20
TW438781B (en) 2001-06-07
HRP980404A2 (en) 1999-04-30
NO20000356D0 (no) 2000-01-24
EE04238B1 (et) 2004-02-16
ES2187983T3 (es) 2003-06-16
JP3895923B2 (ja) 2007-03-22
DK1000048T3 (da) 2003-03-03
NZ502384A (en) 2001-05-25
TR200000229T2 (tr) 2000-06-21
US20010051626A1 (en) 2001-12-13
ID24583A (id) 2000-07-27
IS5358A (is) 2000-01-24
KR20010022171A (ko) 2001-03-15
CA2296518A1 (en) 1999-02-04
HK1025963A1 (en) 2000-12-01
AR046193A2 (es) 2005-11-30
US6410532B2 (en) 2002-06-25
AR013370A1 (es) 2000-12-27
ATE228510T1 (de) 2002-12-15
DE69809755D1 (de) 2003-01-09
NO315609B1 (no) 2003-09-29
US6313118B1 (en) 2001-11-06
AU739569B2 (en) 2001-10-18
AU8370398A (en) 1999-02-16
TNSN98141A1 (fr) 2005-03-15
SK283918B6 (sk) 2004-05-04
US20010051623A1 (en) 2001-12-13
HUP0004334A3 (en) 2002-10-28
UA69389C2 (uk) 2004-09-15
PT1000048E (pt) 2003-03-31
RU2194696C2 (ru) 2002-12-20

Similar Documents

Publication Publication Date Title
BR9811042A (pt) Composto, formulação farmacêutica, uso de um composto, e, processos para o tratamento de distúrbios no sistema nervoso central e/ou de incontinência urinária, vasoespasmos e controle do crescimento de tumores e para a preparação do composto
YU61595A (sh) Nova naftilna jedinjenja, njihovi intermedijeri farmaceutske kompozicije, i postupci za dobijanje tih jedinjenja
EP1566379A4 (en) QUINOLINE AND QUINAZOLINE DERIVATIVES INHIBITING THE AUTOPHOSPHORYLATION OF FLT3 AND MEDICAL COMPOSITIONS CONTAINING SAME
BR0214988A (pt) S-enanciÈmero de um composto, composto, formulação farmacêutica, método de tratamento ou prevenção de distúrbios de lipìdeo, uso de um composto, método de tratamento ou prevenção de diabetes tipo 2, processo para a preparação de um composto, e, composição farmacêutica
BR9812238A (pt) Composto, uso deste, processo para a preparação do mesmo, formulação farmacêutica, e, processos para o tratamento de distúrbios do sistema nervoso central e/ou incontinência urinária, ou vasoespasmo, ou para controle de crescimento de tumores, e para o tratamento de distúrbios mediados por 5-hidroxitriptamina
BRPI0409227B8 (pt) "composto, composição farmacêutica, uso de um composto e processo para a preparação de um composto de fórmula (i)"
BRPI0411255A (pt) composto, composição farmacêutica, uso de um composto, métodos de tratar um distúrbio de um paciente, e, processo para a preparação de um composto
NO20051263L (no) Ny anvendelse av benzotiazolderivater
BR0317294A (pt) Composto, formulação farmacêutica, uso de um composto, métodos de prevenção e/ou tratamento de condições associadas com a glicogênio sintase quinase-3 e de prevenção e/ou tratamento de doenças, e, uso dos intermediários
BR0210874A (pt) Derivados de tiazol-benzamida e composições farmacêuticas para a inibição da proliferação celular e métodos para o seu uso
DE60107820D1 (de) Neue verwendung von phenylheteroalkylamin-derivaten
AR006360A1 (es) Derivados de 1,2,3,4-tetrahidronaftaleno substituidos, uso de los mismos para la preparacion de medicamentos y procedimiento para su preparacion.
BR9812239A (pt) Composto, formulação farmacêutica, uso do composto, processos para o tratamento de distúrbios, para o tratamento de distúrbios mediados por 5-hidroxitriptamina, e, para a preparação do composto
AR036351A1 (es) Isoxazolopiridinonas, el uso de las mismas para la fabricacion de un medicamento, composiciones y combinaciones farmaceuticas
HRP20050831A2 (en) Novel oxazole derivatives, their manufacture and use as pharmaceutical agents
FI971155A0 (fi) Menetelmä tamoksifeenin ja tamoksifeenianalogien uterotrofisen vaikutuksen minimoiseksi
BRPI0410657A (pt) composto, composição farmacêutica, uso de um composto, método para tratar um distúrbio de um paciente, e, processo para a preparação de um composto
BR0315400A (pt) Composto, composição farmacêutica, e, métodos para tratar ou prevenir câncer em um paciente e para inibir o crescimento de uma célula de câncer ou célula neoplástica
BR0212932A (pt) Derivados de alquilaminopiridazinona substituìdos, processo para a preparação destes, composição farmacêutica contendo os mesmos e seus usos
BR0209102A (pt) Novos derivados 5-tio-beta.-d-xilopiranosìdeos, procedimento de preparação, composições farmacêuticas que os contém e sua utilização em terapêutica
BRPI0508925A (pt) derivados de éter, produção e uso deles como agentes farmacêuticos
CA2479341A1 (en) Dithiolopyrrolone derivatives useful in the treatment of proliferative diseases
DE60103035D1 (de) Neue verwendung von phenylheteroalkylamin-derivaten
DE69002340D1 (de) Pyrimidin-derivate, 2-(4-(alpha-heteroaryl-alpha-aryl-(alpha-alkyl)-methoxy)-butyl)-1-piperazinyl) mit serotoninergischer wirkung.
DE60005525D1 (de) 2-aminotetraline zur behandlung von glaukom

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 8A E 9A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 1912 DE 28/08/2007.